| Reference |
|---|
Oguri N, Gi T, Nakamura E, Furukoji E, Goto H, Maekawa K, et al. Expression of fibroblast activation protein-α in human deep vein thrombosis. Thromb Res. 2024;241:109075 pubmed publisher |
Zhang B, Chuang G, Biju A, Biner D, Cheng J, Wang Y, et al. Cholesterol reduction by immunization with a PCSK9 mimic. Cell Rep. 2024;43:114285 pubmed publisher |
Bestas B, Wimberger S, Degtev D, Madsen A, Rottner A, Karlsson F, et al. A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo. Nat Commun. 2023;14:5474 pubmed publisher |
Ballantyne C, Ditmarsch M, Kastelein J, Nelson A, Kling D, Hsieh A, et al. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023;17:491-503 pubmed publisher |
Larrea Sebal A, Trenti C, Jebari Benslaiman S, Bertolini S, Calandra S, Negri E, et al. Functional Characterization of p.(Arg160Gln) PCSK9 Variant Accidentally Found in a Hypercholesterolemic Subject. Int J Mol Sci. 2023;24: pubmed publisher |
Atreya M, Cvijanovich N, Fitzgerald J, Weiss S, Bigham M, Jain P, et al. Detrimental effects of PCSK9 loss-of-function in the pediatric host response to sepsis are mediated through independent influence on Angiopoietin-1. Res Sq. 2023;: pubmed publisher |
x15a widerska M, Mostowska A, Skrypnik D, Jagodzi x144 ski P, Bogda x144 ski P, Grzegorzewska A. Energy Homeostasis Gene Nucleotide Variants and Survival of Hemodialysis Patients-A Genetic Cohort Study. J Clin Med. 2022;11: pubmed publisher |
Spannella F, Giulietti F, Galeazzi R, Passarelli A, Re S, Di Pentima C, et al. Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Inversely Associated with N-Terminal Pro B-Type Natriuretic Peptide in Older Men and Women. Biomedicines. 2022;10: pubmed publisher |
Silva Berm xfa dez L, Vargas Villanueva A, S xe1 nchez Vallejo C, Palacio A, Buitrago A, Mendivil C. Peri-event plasma PCSK9 and hsCRP after an acute myocardial infarction correlate with early deterioration of left ventricular ejection fraction: a cohort study. Lipids Health Dis. 2022;21:61 pubmed publisher |
Baran J, Niewiara x, Podolec J, Siedli x144 ski M, J xf3 zefczuk E, Bernacik A, et al. Serum and Vascular Stiffness Biomarkers Associated with the Severity of Degenerative Aortic Valve Stenosis and Cardiovascular Outcomes. J Cardiovasc Dev Dis. 2022;9: pubmed publisher |
Lammi C, Fassi E, Li J, Bartolomei M, Benigno G, Roda G, et al. Computational Design and Biological Evaluation of Analogs of Lupin Peptide P5 Endowed with Dual PCSK9/HMG-CoAR Inhibiting Activity. Pharmaceutics. 2022;14: pubmed publisher |
Lebeau P, Byun J, Platko K, Saliba P, Sguazzin M, Macdonald M, et al. Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance. Nat Commun. 2022;13:770 pubmed publisher |
Metzner T, Leitner D, Mellitzer K, Beck A, Sourij H, Stojakovic T, et al. Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study. Biomedicines. 2022;10: pubmed publisher |
Canclini L, Malvandi A, Uboldi P, Jabnati N, Grigore L, Zambon A, et al. The Association of Proprotein Convertase Subtilisin/Kexin Type 9 to Plasma Low-Density Lipoproteins: An Evaluation of Different Methods. Metabolites. 2021;11: pubmed publisher |
Liu M, Peng J, Guo Y, Zhu C, Wu N, Xu R, et al. Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia. J Transl Med. 2021;19:498 pubmed publisher |
Peng J, Liu M, Liu H, Guo Y, Wu N, Dong Q, et al. Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study. Thromb J. 2021;19:90 pubmed publisher |
Verges B, Hassid J, Rouland A, Bouillet B, Simoneau I, Petit J, et al. Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins. Diabetes Metab. 2021;48:101284 pubmed publisher |
Melexopoulou C, Marinaki S, Oikonomou E, Bonios M, Theofilis P, Miliou A, et al. PCSK9 and inflammatory biomarkers in the early post kidney transplantation period. Eur Rev Med Pharmacol Sci. 2021;25:4762-4772 pubmed publisher |
Dounousi E, Tellis C, Pavlakou P, Duni A, Liakopoulos V, Mark P, et al. Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients. Oxid Med Cell Longev. 2021;2021:6677012 pubmed publisher |
Rothgangl T, Dennis M, Lin P, Oka R, Witzigmann D, Villiger L, et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat Biotechnol. 2021;39:949-957 pubmed publisher |
Lammi C, Aiello G, Bollati C, Li J, Bartolomei M, Ranaldi G, et al. Trans-Epithelial Transport, Metabolism, and Biological Activity Assessment of the Multi-Target Lupin Peptide LILPKHSDAD (P5) and Its Metabolite LPKHSDAD (P5-Met). Nutrients. 2021;13: pubmed publisher |
Ciric M, Ostojic M, Baralic I, Kotur Stevuljevic J, Djordjevic B, Markovic S, et al. Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy. Nutrients. 2021;13: pubmed publisher |
Silvino J, Carvalho M, Reis E, Mota A, Gomes K, Duarte R, et al. Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation?. Thromb Res. 2021;200:156-163 pubmed publisher |
Ibold B, Tiemann J, Faust I, Ceglarek U, Dittrich J, Gorgels T, et al. Genetic deletion of Abcc6 disturbs cholesterol homeostasis in mice. Sci Rep. 2021;11:2137 pubmed publisher |
Levine J, Oleaga C, Eren M, Amaral A, Shang M, Lux E, et al. Role of PAI-1 in hepatic steatosis and dyslipidemia. Sci Rep. 2021;11:430 pubmed publisher |
Peng J, Liu M, Jin J, Cao Y, Guo Y, Wu N, et al. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. Cardiovasc Diabetol. 2020;19:167 pubmed publisher |
Fasolato S, Pigozzo S, Pontisso P, Angeli P, Ruscica M, Savarino E, et al. PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. J Clin Med. 2020;9: pubmed publisher |
Chemello K, Beesk xe9 S, Trang Tran T, Blanchard V, Villard E, Poirier B, et al. Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab. JACC Basic Transl Sci. 2020;5:549-557 pubmed publisher |
Dozio E, Ruscica M, Vianello E, Macchi C, Sitzia C, Schmitz G, et al. PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation. Mediators Inflamm. 2020;2020:1348913 pubmed publisher |
Cui C, Jin J, Guo L, Sun J, Wu N, Guo Y, et al. Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a. J Transl Med. 2020;18:195 pubmed publisher |
Krahel J, Baran A, Kamiński T, Maciaszek M, Flisiak I. Methotrexate Decreases the Level of PCSK9-A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data. J Clin Med. 2020;9: pubmed publisher |
Lupo M, Biancorosso N, Brilli E, Tarantino G, Adorni M, Vivian G, et al. Cholesterol-Lowering Action of a Novel Nutraceutical Combination in Uremic Rats: Insights into the Molecular Mechanism in a Hepatoma Cell Line. Nutrients. 2020;12: pubmed publisher |
Cao Y, Jin J, Sun D, Liu H, Guo Y, Wu N, et al. Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy. J Transl Med. 2019;17:367 pubmed publisher |
Li C, Hu Z, Zhang W, Yu J, Yang Y, Xu Z, et al. Regulation of Cholesterol Homeostasis by a Novel Long Non-coding RNA LASER. Sci Rep. 2019;9:7693 pubmed publisher |
Carreras A, Pane L, Nitsch R, Madeyski Bengtson K, Porritt M, Akçakaya P, et al. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model. BMC Biol. 2019;17:4 pubmed publisher |
Genga K, Lo C, Cirstea M, Leitão Filho F, Walley K, Russell J, et al. Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors. EBioMedicine. 2018;38:257-264 pubmed publisher |
Akçakaya P, Bobbin M, Guo J, Malagon Lopez J, Clement K, Garcia S, et al. In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature. 2018;561:416-419 pubmed publisher |
Vlachopoulos C, Koutagiar I, Terentes Printzios D, Skoumas I, Rigatou A, Miliou A, et al. Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidemias. Hellenic J Cardiol. 2018;: pubmed publisher |
Lebeau P, Platko K, Al Hashimi A, Byun J, Lhotak S, Holzapfel N, et al. Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained. J Biol Chem. 2018;293:7329-7343 pubmed publisher |
Yuan F, Guo L, Park K, Woollard J, Taek Geun K, Jiang K, et al. Ossabaw Pigs With a PCSK9 Gain-of-Function Mutation Develop Accelerated Coronary Atherosclerotic Lesions: A Novel Model for Preclinical Studies. J Am Heart Assoc. 2018;7: pubmed publisher |
Papazyan R, Liu X, Liu J, Dong B, Plummer E, Lewis R, et al. FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver. J Lipid Res. 2018;59:982-993 pubmed publisher |
Zimmer M, Bista P, Benson E, Lee D, Liu F, Picarella D, et al. CAT-2003: A novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice. Hepatol Commun. 2017;1:311-325 pubmed publisher |
Ricci C, Ruscica M, Camera M, Rossetti L, Macchi C, Colciago A, et al. PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep. 2018;8:2267 pubmed publisher |
Zanni M, Stone L, Toribio M, Rimmelin D, Robinson J, Burdo T, et al. Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. Open Forum Infect Dis. 2017;4:ofx227 pubmed publisher |
Gustafsen C, Olsen D, Vilstrup J, Lund S, Reinhardt A, Wellner N, et al. Heparan sulfate proteoglycans present PCSK9 to the LDL receptor. Nat Commun. 2017;8:503 pubmed publisher |
Ruscica M, Ferri N, Fogacci F, Rosticci M, Botta M, Marchianò S, et al. Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. J Am Heart Assoc. 2017;6: pubmed publisher |
Lebeau P, Al Hashimi A, Sood S, Lhotak S, Yu P, Gyulay G, et al. Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism. J Biol Chem. 2017;292:1510-1523 pubmed publisher |
Yang S, Du Y, Li S, Zhang Y, Xu R, Zhu C, et al. Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima-media thickness in hypertensives. Hypertens Res. 2016;39:598-605 pubmed publisher |
Loregger A, Cook E, Nelson J, Moeton M, Sharpe L, Engberg S, et al. A MARCH6 and IDOL E3 Ubiquitin Ligase Circuit Uncouples Cholesterol Synthesis from Lipoprotein Uptake in Hepatocytes. Mol Cell Biol. 2016;36:285-94 pubmed publisher |
Almontashiri N, Vilmundarson R, Ghasemzadeh N, Dandona S, Roberts R, Quyyumi A, et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS ONE. 2014;9:e106294 pubmed publisher |
Zhang Y, Liu J, Li S, Xu R, Sun J, Li J. Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats. Lipids Health Dis. 2014;13:35 pubmed publisher |
